OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV	109
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?	76
Real world use of dolutegravir two drug regimens	48
Multisector global collaboration to advance the inclusion of pregnant and lactating people in HIV prevention research	47
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine	45
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery	44
Reduced bone density accrual among peripubertal boys with HIV in Zimbabwe: Erratum	44
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France	40
Cerebral toxoplasmosis in the twenty-first century: long-term clinical outcomes in a retrospective cohort study in the Netherlands	39
HIV-1 gp120 amplifies astrocyte elevated gene-1 activity to compromise the integrity of the outer blood–retinal barrier	36
Trends in population HIV viral suppression: a longitudinal analysis	33
Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum	33
A new frontier in HIV care: the predictive power of renal biomarkers on heart health	32
Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV	32
Quantifying missed opportunities for tuberculosis among people with HIV in the US President's Emergency Plan for AIDS Relief	31
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies	30
Diagnostic accuracy of the re-engineered urinary FujiLAM2 assay amongst hospitalized adults with advanced HIV disease	29
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infection	29
Key milestones and participant engagement strategies in research with HIV-affected adolescents and young adults from low-to-middle income countries	29
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy	28
Explaining racial and ethnic disparities in antiretroviral therapy adherence and viral suppression among U.S. men who have sex with men	28
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	27
Elevated stress-responsive biomarkers are associated with HIV acquisition in young women in rural South Africa	27
Associations between social determinants of health and comorbidity and multimorbidity in people of black ethnicities with HIV	27
Virtual case management: a differentiated approach to HIV prevention, treatment, and care	26

Life expectancy of people with HIV on antiretroviral therapy in Spain